<DOC>
	<DOCNO>NCT01433770</DOCNO>
	<brief_summary>Alefacept , also know Amevive® , medication approve Food Drug Administration ( FDA ) United States country treatment psoriasis , chronic inflammatory immunological skin condition result chronic dry , red patch cover scale . Alefacept approve FDA treatment psoriasis anti-rejection medication transplant patient . It test new kidney transplant patient supplement approve anti-rejection drug . Alefacept use investigational drug study . The reason study test whether use Alefacept inhibit T cell , know memory cell , use test name ELISPOT-IFN . In patient psoriasis , Alefacept inhibit memory cell . If memory cell specific donor inhibited drug , might prevent rejection promote acceptance transplant kidney unique manner .</brief_summary>
	<brief_title>Alefacept Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Alefacept</mesh_term>
	<criteria>Able willing sign inform consent Adult ( &gt; 18years ) kidneyalone transplant recipient 6 month posttransplant Persistently positive donorstimulated ELISPOTIFN ( ≥30 spots/300K cell ) 2 positive assay separate least one week Female subject child bear potential must negative urine serum pregnancy test within 7 day prior enrollment must agree maintain effective birth control study Baseline CD4 count &lt; 250 cells/uL Acute rejection episode within 3 month prior enrollment Clinically overt infection within 3 month prior enrollment History BK polyoma viremia Recipient donor know seropositive human immunodeficiency virus ( HIV ) Subject current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Any major illnesses/condition , investigator 's judgment , substantially increase risk associate subject 's participation completion study , could preclude evaluation subject 's response</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>